Anika Therapeutics (ANIK) Receivables - Net (2016 - 2025)
Anika Therapeutics (ANIK) has disclosed Receivables - Net for 16 consecutive years, with $24.8 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Net rose 5.18% to $24.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.8 million, a 5.18% increase, with the full-year FY2025 number at $24.8 million, up 5.18% from a year prior.
- Receivables - Net was $24.8 million for Q4 2025 at Anika Therapeutics, up from $23.1 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $38.4 million in Q2 2023 to a low of $22.7 million in Q1 2025.
- A 5-year average of $29.6 million and a median of $29.4 million in 2021 define the central range for Receivables - Net.
- Peak YoY movement for Receivables - Net: surged 40.61% in 2021, then tumbled 32.7% in 2025.
- Anika Therapeutics' Receivables - Net stood at $29.8 million in 2021, then increased by 21.42% to $36.2 million in 2022, then fell by 27.25% to $26.4 million in 2023, then dropped by 10.49% to $23.6 million in 2024, then grew by 5.18% to $24.8 million in 2025.
- Per Business Quant, the three most recent readings for ANIK's Receivables - Net are $24.8 million (Q4 2025), $23.1 million (Q3 2025), and $24.8 million (Q2 2025).